Indoco Remedies Q3 results 2025 on 22 Jan, 2025: loss at  ₹26.39Cr
Wed, Jan 22, 2025 11:20 AM

Indoco Remedies Q3 results 2025 on 22 Jan, 2025: loss at ₹26.39Cr

A Flip by Swapnil Tiwari
Get it on Google Play
Indoco Remedies reported a Q3 loss of ₹26.39 crore, a 10.64% year-over-year decline, due to rising Selling, General & Administrative expenses, which increased by 5.03% quarter-over-quarter and 8.43% year-over-year. Operating income and EPS also saw significant declines, with analysts issuing a cautious "Hold" recommendation.

More great flips

Nexus Surgical Standalone December 2024 Net Sales at Rs 1.48 crore

Nexus Surgical Standalone December 2024 Net Sales at Rs 1.48 crore

Reported Standalone quarterly numbers for Nexus Surgical and Medicare Limited are: Net Sales at Rs 1.48 crore in December 2024 up 2.62% from Rs. 1.45 crore in December 2023. Quarterly Net Profit at Rs. 0.11 crore in December 2024 up 143.78% from Rs. 0.05 crore in December 2023. EBITDA stands at Rs. 0.15 crore in December 2024 up 150% from Rs. 0.06 crore in December 2023.

Open Flip
Indiamart Intermesh Standalone December 2024 Net Sales at Rs 337.20 crore

Indiamart Intermesh Standalone December 2024 Net Sales at Rs 337.20 crore

Reported Standalone quarterly numbers for Indiamart Intermesh are: Net Sales at Rs 337.20 crore in December 2024 up 15.72% from Rs. 291.40 crore in December 2023. Quarterly Net Profit at Rs. 124.90 crore in December 2024 up 36.35% from Rs. 91.60 crore in December 2023. EBITDA stands at Rs. 166.90 crore in December 2024 up 32.88% from Rs. 125.60 crore in December 2023.

Open Flip
Buy Indostar Capital Finance; target of Rs 325: Motilal Oswal

Buy Indostar Capital Finance; target of Rs 325: Motilal Oswal

Indostar Capital Finance reported a mixed quarter with strong business momentum, but higher credit costs due to lower collection efficiency and delinquencies in the vehicle finance portfolio, resulting in annualized credit cost of 1.8%. Despite this, the company is expected to achieve a CAGR of 30%/33% in AUM/PAT over FY24-27, leading to a reiteration of the BUY rating with a target price- INR325.

Open Flip

Join our Smart Investment Community

More than 2 Million users are using FlipItMoney to stay updated about the business and finance world! Join FlipItMoney now and take smart investment decisions!
Icon